NSE PFIZER · BSE 500680 · Major Drugs · NIFTY 500

Pfizer Share Price

Market closed · updated 25 Sep, 4:47 PM IST

₹4,005.00 ▼ −₹46.59 · 1.15% NSE · as of 25 Sep 2026, 9:59 AM · BSE ₹4,001.00

Today's range

₹3,985.00Low₹4,057.25High

52-week range

₹3,962.00Low · 16 Sep 2026₹5,561.55High · 13 Oct 2025

Pfizer Overview

Where the price stands, how it has moved and how it sits against its averages.

Pfizer shares last traded at ₹4,005.00 on the NSE, down 1.15% on the day. That is 28.0% below the 52-week high of ₹5,561.55 and 1.1% above the 52-week low of ₹3,962.00. The stock trades at 27.63× earnings, below the sector average of 36.18. Its market value is ₹18,299 Cr.

Price returns

1 Day▼ −1.15%

5 Days▲ +0.78%

This month▼ −13.62%

3 Months▼ −9.29%

6 Months▼ −14.08%

This year▼ −18.88%

1 Year▼ −19.16%

Against the market: 1 Month ▼ −10.75% · 3 Months ▼ −4.95% · 6 Months ▼ −12.11% · This year ▼ −6.04% · 1 Year ▼ −10.22%

Shading grows with the size of the move. Prices refresh every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next update from Mon 28 Sep, 9:15 AM.

Moving averages — price is above 0 of 6

300-day average₹4,737.59 ▼ price 15.5% below
50-day average₹4,619.35 ▼ price 13.3% below
100-day average₹4,611.27 ▼ price 13.1% below
20-day average₹4,350.33 ▼ price 7.9% below
10-day average₹4,045.99 ▼ price 1.0% below
5-day average₹4,015.46 ▼ price 0.3% below
Today's price₹4,005.00

Averages above today's price sit higher on the ladder. Price above most of its averages is usually read as an upward trend.

Pfizer Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore

2,611

2,520

Net profit₹ crore · losses below zero

768

722

Year by year

Fiscal year	Revenue	Growth	Net profit	Net margin	EPS	Dividend
FY 2026	₹2,520 Cr	▲ +10.4%	₹722 Cr	28.7%	₹157.92	₹75.00
FY 2025	₹2,281 Cr	▲ +4.0%	₹768 Cr	33.6%	₹167.79	₹35.00
FY 2024	₹2,193 Cr	▼ −9.6%	₹551 Cr	25.1%	₹120.51	₹35.00
FY 2023	₹2,425 Cr	▼ −7.1%	₹624 Cr	25.7%	₹136.38	₹35.00
FY 2022	₹2,611 Cr	▲ +16.6%	₹613 Cr	23.5%	₹133.89	₹35.00
FY 2021	₹2,239 Cr	▲ +4.0%	₹498 Cr	22.2%	₹108.77	₹30.00
FY 2020	₹2,152 Cr	—	₹509 Cr	23.7%	₹111.28	₹10.00

Revenue₹ crore

653

Net profit₹ crore · losses below zero

331

204

Quarter by quarter

Quarter	Revenue	vs prev. qtr	Net profit	Net margin	EPS
Q1 FY27	₹653 Cr	▲ +3.8%	₹204 Cr	31.3%	₹44.69
Q4 FY26	₹629 Cr	▼ −2.4%	₹200 Cr	31.8%	₹43.68
Q3 FY26	₹645 Cr	▲ +0.4%	₹142 Cr	22.0%	₹31.01
Q2 FY26	₹642 Cr	▲ +6.5%	₹189 Cr	29.4%	₹41.32
Q1 FY26	₹603 Cr	▲ +1.9%	₹192 Cr	31.8%	₹41.91
Q4 FY25	₹592 Cr	▲ +10.0%	₹331 Cr	55.9%	₹72.36
Q3 FY25	₹538 Cr	▼ −8.6%	₹128 Cr	23.7%	₹27.89
Q2 FY25	₹589 Cr	—	₹158 Cr	26.9%	₹34.61

Balance sheet — FY26

Owes (liabilities)Shareholders' equity

15%

85%

Total assets₹4,922 Cr
Total liabilities₹719 Cr
Shareholders' equity₹4,203 Cr
Total debt₹70 Cr
Cash & investments₹3,114 Cr
Current ratio6.06×
Revenue growth, 5 yr2.39% a year
EPS growth, 5 yr7.74% a year
Operating margin (TTM)32.49%
Net margin (TTM)28.61%

Cash flow — FY26

Operating activities

▲ ₹968 Cr

Investing activities

▼ −₹562 Cr

Financing activities

▼ −₹798 Cr

Free cash flow

▲ ₹942 Cr

Net change in cash

▼ −₹392 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY20–FY26

₹ crore	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Total revenue	2,151.65	2,238.55	2,610.99	2,424.76	2,193.17	2,281.35	2,519.65
Cost of revenue	851.68	858.73	1,008.68	927.65	842.01	859.11	884.31
Gross profit	1,299.97	1,379.82	1,602.31	1,497.11	1,351.16	1,422.24	1,635.34
Operating expenses	1,639.57	1,625.23	1,879.37	1,680.32	1,601.81	1,587.07	1,722.45
Operating income	512.08	613.32	731.62	744.44	591.36	694.28	797.20
Depreciation	101.86	108.02	113.61	104.02	62.28	60.79	57.73
Profit before tax	642.49	668.72	772.89	824.01	746.07	1,016.09	975.67
Tax	133.36	171.11	160.33	200.08	194.74	248.49	253.24
Net profit	509.13	497.61	612.56	623.93	551.33	767.60	722.43
EPS (₹)	111.28	108.77	133.89	136.38	120.51	167.79	157.92
Dividend per share (₹)	10.00	30.00	35.00	35.00	35.00	35.00	75.00

₹ crore	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Total assets	4,405.40	3,265.90	3,900.51	4,000.73	4,228.78	4,911.11	4,921.88
Current assets	3,048.25	1,924.71	2,361.44	2,493.34	2,737.81	3,512.85	3,803.22
Cash & short-term investments	2,197.65	1,102.54	1,620.39	1,846.42	2,034.05	2,788.45	3,113.73
Inventory	435.86	444.67	457.91	424.63	441.62	487.29	472.66
Property, plant & equipment	215.28	195.14	220.07	185.46	151.35	179.46	156.13
Total liabilities	1,009.91	872.86	1,036.10	793.43	633.24	693.70	718.98
Current liabilities	873.36	774.34	852.89	657.35	546.56	569.51	627.48
Total debt	127.93	105.91	166.99	134.47	94.54	108.40	70.23
Total equity	3,395.49	2,393.04	2,864.41	3,207.30	3,595.54	4,217.41	4,202.90

₹ crore	FY20	FY21	FY22	FY23	FY24	FY25	FY26
From operations	323.18	427.33	667.08	355.68	256.84	659.75	967.57
From investing	1,530.32	−468.84	−575.02	−36.05	53.70	−71.34	−561.67
From financing	−163.52	−1,571.07	−180.51	−345.79	−235.14	−205.34	−798.31
Capital expenditure	−38.39	−17.70	−15.31	−64.98	−18.93	−28.15	−25.23
Dividends paid	−102.93	−1,519.35	−159.74	−297.21	−183.43	−160.25	−751.64
Net change in cash	1,689.98	−1,612.58	−88.45	−26.16	75.40	383.07	−392.41

What Analysts Say

5 analysts

Recommendations from 5 analysts who cover Pfizer.

Buy average rating 2.00 on a 1–5 scale

Strong buyBuyHoldSellStrong sell

▲ 3 bullish (60.0%) · 2 hold (40.0%) · ▼ 0 bearish (0.0%)

Votes

Strong Buy

2 (40%)

Buy

1 (20%)

Hold

2 (40%)

Sell

0 (0%)

Strong Sell

0 (0%)

How the votes changed

Rating	3M ago	2M ago	1M ago	1W ago	Now	3-month change
Strong Buy	3	3	3	2	2	▼ −1
Buy	1	1	1	1	1	—
Hold	1	1	1	2	2	▲ +1
Sell	0	0	0	0	0	—
Strong Sell	0	0	0	0	0	—

Analyst ratings are opinions, not a guarantee of returns.

Pfizer vs Peers

Side by side with other major drugs companies. The small bars compare each column.

Company	Price	Change	Market cap	P/E	P/B	ROE (5 yr)	Net margin	Div. yield	Rating
Pfizer	₹4,005.00	▼ −1.15%	₹18,299 Cr	27.63	4.40	19.08%	28.61%	1.85%	This stock
Aurobindo Pharma	₹1,711.30	▼ −0.51%	₹98,464 Cr	25.09	2.35	10.25%	10.41%	0.26%	Bullish
Neuland Laboratories	₹21,800.00	▼ −0.50%	₹27,862 Cr	64.28	12.62	19.28%	17.99%	0.18%	Neutral
Unichem Laboratories	₹548.00	▼ −1.07%	₹3,825 Cr	54.27	1.53	1.01%	11.48%	—	Bullish
Jagsonpal Pharmaceuticals	₹241.95	▼ −0.78%	₹1,592 Cr	34.27	5.43	18.10%	15.00%	1.12%	Bullish
Themis Medicare	₹116.50	▼ −1.60%	₹1,070 Cr	632.19	2.54	11.91%	0.33%	0.45%	Neutral

Rating = the data provider's overall technical view of each peer. Company names link to their own pages.

Shareholding Pattern

Who owns Pfizer shares, quarter by quarter (latest on top).

PromoterFIIMFOther

Jun '26

63.9%

12.7%

21.8%

Mar '26

Dec '25

Sep '25

Holder	Sep '25	Dec '25	Mar '26	Jun '26	Change
Promoter	63.92%	63.92%	63.92%	63.92%	0.00 pts
FII	2.60%	2.71%	2.81%	1.65%	▼ −1.16 pts
MF	11.74%	11.71%	11.52%	12.68%	▲ +1.16 pts
Other	21.74%	21.66%	21.75%	21.75%	0.00 pts

Pfizer Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

PfizerBenchmarkComfortable → stretched

Valuation Is the price reasonable?

P/E (TTM)Price ÷ yearly earnings per share

27.63

▼ 24% below the sector average of 36.18

P/E, 12-month rangeLow 23.33 · high 42.34

23%

Today's P/E sits 23% of the way from its low to its high

P/BPrice ÷ book value per share

4.40

P/SPrice ÷ sales per share

7.20

P/CFPrice ÷ cash flow per share

23.35

PEGP/E ÷ earnings growth (≈1 is fair)

5.03

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods

64.46%

▲ above its 5-yr average of 62.41%

Operating marginKept after running costs

32.49%

▲ above its 5-yr average of 29.58%

Pre-tax marginKept before tax

38.63%

▲ above its 5-yr average of 36.03%

Net marginKept as profit

28.61%

▲ above its 5-yr average of 27.25%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money

17.16%

▼ below its 5-yr average of 19.08%

Return on assetsProfit on everything it owns

14.69%

▼ below its 5-yr average of 15.51%

Return on investmentProfit on long-term capital

16.73%

▼ below its 5-yr average of 18.41%

Growth Is the business getting bigger?

Revenue — last 12 months

+10.7%

▲ growing

Revenue — 3 yr, a year

+1.3%

▲ growing

Revenue — 5 yr, a year

+2.4%

▲ growing

EPS — last 12 months

−9.1%

▼ shrinking

EPS — 3 yr, a year

+5.0%

▲ growing

EPS — 5 yr, a year

+7.7%

▲ growing

Dividend — 3 yr, a year

+28.9%

▲ growing (off the scale)

Book value — 5 yr, a year

+11.9%

▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money

0.02×

✓ Low debt

Current ratioShort-term assets for every ₹1 due within a year

6.06×

✓ Comfortable

Quick ratioLike the current ratio, without inventory

5.31×

✓ Comfortable

Interest coverOperating profit ÷ interest to pay

112.40×

✓ Strong

Payout ratioShare of profit paid as dividend

47.49%

✓ Balanced

Per share What each share stands for

EPS (TTM)

₹160.70

Book value

₹919.67

Cash flow

₹173.28

Dividend

₹75.00

Revenue

₹561.73

The share price is 4.35× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 111 metrics from the data provider

Valuation

P/E excluding extraordinary items, most recent fiscal year25.62

Current Dividend Yield - Common Stock Primary Issue, LTM1.85

Price to Book - most recent fiscal year4.40

P/E Basic excluding extraordinary items - TTM27.63

P/E including extraordinary items - TTM25.18

P/E excluding extraordinary items low, trailing 12 months23.33

Price to Tangible Book - most fiscal year5.06

Dividend Yield - 5 Year Average1.06

Price to sales - most recent fiscal year7.35

Dividend Yield - indicated annual dividend divided by closing price1.85

Price to Cash Flow per share - trailing 12 month23.35

Peg Ratio5.03

Price to Free Cash Flow per Share - most recent fiscal year97.07

P/E Normalized, most recent fiscal year24.39

P/E excluding extraordinary items high, trailing 12 months42.34

P/E excluding extraordinary items, most recent fiscal year quarter25.18

Price to sales - trailing 12 month7.20

Net Debt, LFY−30,435.00

Per share

Dividend Per Share - 5 year average43.00

Cash Flow per share - trailing 12 month173.28

Cash Flow per share - most recent fiscal year170.54

EPS including extraordinary items - trailing 12 month160.70

EPS including extraordinary items - most recent fiscal year157.92

EBITD per share - trailing 12 month205.83

Revenue/share - trailing 12 month561.73

EPS excluding extraordinary items - trailing 12 month160.70

EPS Basic excluding extraordinary items - most recent fiscal year157.92

EPS Basic excluding extraordinary items - trailing 12 month160.70

Book value per share - most recent fiscal year918.71

Dividend per share - most recent fiscal year75.00

Revenue/share - most recent fiscal year550.77

EPS Normalized - most recent fiscal year165.87

Book value (tangible) per share - most recent fiscal year800.27

Dividends per share - trailing 12 month75.00

EPS excluding extraordinary items - most recent fiscal year157.92

Cash per share - most recent fiscal year680.63

Margins

Operating margin - trailing 12 month32.49

Gross Margin - 5 year average62.41

Operating margin - 1st historical fiscal year31.64

Operating Margin - 5 year average29.58

Net Profit Margin % - 1st historical fiscal year28.67

Gross Margin - 1st historical fiscal year64.90

Net Profit Margin % - trailing 12 month28.61

Net Profit Margin - 5 year average27.25

Pretax Margin - 5 year average36.03

Pretax margin - 1st historical fiscal year38.72

Pretax margin - trailing 12 month38.63

Free Operating Cash Flow/Revenue, 5 Year Average9.99

Gross Margin - trailing 12 month64.46

Growth

EPS Change %, TTM over TTM−9.09

Revenue growth rate, 5 year2.39

EPS growth rate, 5 year7.74

Revenue Change % - most recent quarter 1 year ago8.31

Growth rate% - dividend, 3 year28.92

Growth rate% - EPS, 3 year5.01

Revenue/share (5 yr growth)2.40

Tangible Book Value, Total Equity, 5 Year CAGR16.30

Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR3.02

Capital Spending growth rate, 5 year7.35

Revenue Change %, TTM over TTM10.69

Growth rate% - Revenue, 3 year1.29

Book value per share growth rate, 5 year11.92

EPS Change % - most recent quarter 1 year ago6.63

Net Profit Margin growth rate, 5 year5.22

Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR4.70

Total Debt, 5 Year CAGR−7.89

Financial strength

Net Interest coverage - most recent fiscal year112.40

Free Cash Flow - most recent fiscal year1,907.00

LT debt/equity - most recent fiscal year0.01

Quick ratio - most recent fiscal year5.31

Payout ratio - trailing 12 month46.67

Current ratio - most recent fiscal year6.06

Current EV/Free Cash Flow, LFY4,701.20

Total debt/total equity - most recent fiscal year0.02

Net Interest coverage - trailing 12 month114.96

Payout ratio - most recent fiscal year47.49

Returns & efficiency

Return on average equity - 5 year average19.08

Net Income/employee - trailing 12 month59,09,566.00

Revenue/employee - most recent fiscal year1,77,31,530.00

Return on investment - most recent fiscal year16.73

Return on average assets - most recent fiscal year14.69

Receivables turnover - most recent fiscal year13.44

Inventory turnover - most recent fiscal year1.84

Revenue/employee - trailing 12 month2,06,57,320.00

Return on average assets - 5 year average15.51

Net Income/employee - most recent fiscal year50,83,955.00

Asset turnover - most recent fiscal year0.51

Return on average equity - most recent fiscal year17.16

Return on investment - 5 year average18.41

Price & volume

Market Cap18,268.49

52 week Low Date16 Sep 2026

Price - 1 Day % Change0.51

Relative (S&P500) price percent change - 13 week−4.95

Avg trading volume last 10 days0.06

Price - 13 week price percent change−9.29

Price - 52 week price percent change−19.16

Avg Trading Volume Last 3 months1.00

Price - 5 Day % Change0.78

Price % Change Month To Date−13.62

Relative (S&P500) price percent change - 04 week−10.75

52 week High Date13 Oct 2025

Price - 26 week price percent change−14.08

PDATE24 Sep 2026

Price - YTD price percent change−18.88

Relative (S&P500) price percent change - 52 week−10.22

NPRICE4,046.20

Relative (S&P500) price percent change - 26 week−12.11

52 week Low3,955.50

52 week High5,578.50

Beta0.79

Relative (S&P500) price percent change - Year to Date−6.04

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year

₹75.00

Dividend yield1.85%
Payout ratio47.49%
5-year average dividend₹43.00 a share
Latest dividend₹75.00 per share · 17 Jul 2026

Corporate calendar

28 Jul 2026MeetingAnnual General Meeting
28 Jul 2026BoardQuarterly Results
17 Jul 2026Dividend₹75.00 per share · 750% · Final dividend
12 May 2026BoardAudited Results & Final Dividend
9 Feb 2026BoardQuarterly Results
12 Nov 2025BoardQuarterly Results
13 Aug 2025BoardQuarterly Results
21 Jul 2025MeetingAnnual General Meeting

Show 14 older events

9 Jul 2025Dividend₹35.00 per share · 350% · Final dividend
9 Jul 2025Dividend₹130.00 per share · 1,300% · Special special dividend
19 May 2025BoardAudited Results & Special Dividend
31 Jan 2025BoardQuarterly Results
28 Oct 2024BoardQuarterly Results
28 Aug 2024MeetingAnnual General Meeting
21 Aug 2024Dividend₹35.00 per share · 350% · Final dividend
2 Apr 2024MeetingPostal Ballot
9 Jan 2024MeetingPostal Ballot
18 Aug 2023MeetingAnnual General Meeting
11 Aug 2023Dividend₹35.00 per share · 350% · Final dividend
11 Aug 2023Dividend₹5.00 per share · 50% · Special special dividend
19 Sep 2022Dividend₹30.00 per share · 300% · Special special dividend
11 Aug 2021Dividend₹30.00 per share · 300% · Final dividend

About Pfizer

Major Drugs

Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal Conjugate Vaccine approved for administering to individuals of all ages against pneumococcal disease, an infection caused by streptococcus pneumoniae bacteria. Internal Medicine portfolio includes approximately 17 specialties and seven therapy areas, including respiratory, multivitamin and multimineral, gastrointestinal, pain, neuroscience, cardiovascular and women’s healthcare. Pfizer Hospital Business Unit focuses on providing advanced anti-infectives to institutions such as hospitals and nursing homes. Inflammation and Immunology focuses on discovering and developing novel therapeutics for chronic autoimmune diseases. Its brands include Prevenar13, CorexDX, Dolonex, Enbrel, Becosules and Folvite, among others.

Key people

Amit AgarwalChief Financial Officer, Executive Director - Finance
Meenakshi NevatiaManaging Director, Executive Director
Sharad GoswamiSenior Director - Policy and Public Affairs
Pankaj GuptaSenior Director - Medical Affairs
Manish PaliwalSenior Director - Regulatory Affairs
Pazhania Pillai RenganExecutive Director - Plant Operations

Company facts

NSE symbolPFIZER
BSE code500680
ISININE182A01018
IndustryMajor Drugs
IndexNIFTY 500
Market cap₹18,299 Cr
Revenue (FY26)₹2,520 Cr
Net profit (FY26)₹722 Cr

In the News

Recent headlines about Pfizer — they open on Mint in a new tab.

Karnataka FDA cracks down on fake drug racket: 24 licences hit, ₹5 cr stock seized — what did it find during raid?
Karnataka FDA has suspended eight drug licences and cancelled 16 due to counterfeit medicine distribution. A raid uncovered an illegal facility repacking drugs, with seized items valued at ₹5.05 crore. Authorities have warned of public health risks & urged consumers to buy from licensed pharmacies.
22 Sep 2026 · 4 min read · Mint ↗
VRS payout tax: Is severance pay taxable? Pune ITAT rules ₹65.21 lakh Pfizer retirement payout was not taxable
Pune ITAT has ruled that a ₹65.21 lakh payout received by a Pfizer employee under a voluntary retirement scheme was a capital receipt and not taxable. The tribunal said Section 56(2)(xi) did not apply because the employee had voluntarily resigned under the scheme, rather than being terminated.
27 Aug 2026 · 3 min read · Mint ↗
Week Ahead: Wall Street eyes US jobs data, SpaceX debut earnings and Disney results
The July jobs report will be the week's most closely watched economic release as investors assess the outlook for US interest rates over the coming months
2 Aug 2026 · 2 min read · Mint ↗
Reported VRS payment as salary in ITR? Pune ITAT grants tax relief in ₹65.21 lakh case
Pune ITAT has ruled that a ₹65.21 lakh payment received under a voluntary retirement scheme was a non-taxable capital receipt and not taxable salary or income from other sources. The tribunal also held that an incorrect claim in the ITR cannot override the true legal nature of the receipt.
21 Jul 2026 · 2 min read · Mint ↗
Manhattan skyscraper evacuated after structural columns buckled, being ‘stabilised’ amid fear of collapse
During the Tuesday morning rush hour, emergency crews evacuated a busy Manhattan street block after structural columns buckled inside a skyscraper undergoing construction work, officials said.
8 Jul 2026 · 5 min read · Mint ↗
US stock market today: Dow, S&P 500 futures rise up to 0.6% as crude oil retreats; Intel jumps 4%
US stock futures rose on May 5, driven by falling crude oil prices and strong corporate earnings. S&P 500 futures increased by 0.4%, while Nasdaq-100 and Dow futures gained 0.6% and 0.3%, respectively. Investors remain cautious due to geopolitical tensions in the Middle East.
5 May 2026 · 2 min read · Mint ↗
Big pharma is turning to China for the newest drug ideas
China’s biotechs are faster and have lower costs, and its drug research threatens to soon overtake the West’s
11 Apr 2026 · 6 min read · Mint ↗
Mint Explainer | Anthropic’s $400-million biotech bet: What it means for India’s pharma industry
As foundational AI models muscle into biosciences and pharmaceuticals, what does it mean for India's $55-billion pharmaceutical industry? Mint explains.
8 Apr 2026 · 4 min read · Mint ↗

Stock data comes from the exchange feed via our data provider and may be delayed. It is for information only and is not a recommendation to buy or sell. See all stocks →

Frequently Asked Questions

Pfizer (NSE: PFIZER) last traded at ₹4,005.00 on the NSE, down 1.15% (₹46.59) on the day, as of 25 Sep 2026, 9:59 AM. On the BSE it was ₹4,001.00. The day's range was ₹3,985.00 – ₹4,057.25.

Pfizer's 52-week high is ₹5,561.55 (13 Oct 2025) and its 52-week low is ₹3,962.00 (16 Sep 2026). At ₹4,005.00 the share is 28.0% below its high and 1.1% above its low.

Pfizer's market capitalisation is ₹18,299 Cr (₹18,299 Cr). It is part of the NIFTY 500 index.

Pfizer's P/E ratio (trailing 12 months) is 27.63. The sector average is 36.18, so investors pay 24% less for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹160.70.

Pfizer shares are down 19.16% over the last year, down 18.88% so far this year, down 14.08% over 6 months, down 9.29% over 3 months. Over the last year the stock did 10.22% worse than the market.

In FY26 (year to Mar 2026), Pfizer reported revenue of ₹2,520 Cr (up 10.45% on the year before) and a net profit of ₹722 Cr. Earnings per share were ₹157.92.

Yes. Pfizer's latest dividend is ₹75.00 per share (750%, final dividend), with an ex-date of 17 Jul 2026. The dividend yield is 1.85%. It has paid 8 dividends in the records shown on this page.

Of 5 analysts covering Pfizer, 3 are bullish (2 strong buy, 1 buy), 2 say hold and 0 are bearish. The consensus is Buy (average rating 2.00 on a scale where 1 is Strong Buy and 5 is Strong Sell). Analyst views are opinions, not a guarantee.

As of Jun 2026: Promoter 63.92%, FII 1.65%, MF 12.68%, Other 21.75%.

Pfizer's listed peers in Major Drugs include Aurobindo Pharma, Neuland Laboratories, Unichem Laboratories, Jagsonpal Pharmaceuticals, Themis Medicare. By market capitalisation it ranks #3 of 6 in this group.

Price returns

Moving averages — price is above 0 of 6

Year by year

Quarter by quarter

Balance sheet — FY26

Cash flow — FY26

Votes

How the votes changed

Valuation Is the price reasonable?

Profitability Of every ₹100 of sales, how much is kept?

Returns & efficiency How well does it use its money?

Growth Is the business getting bigger?

Financial strength Can it pay its bills and debts?

Per share What each share stands for

Valuation

Per share

Margins

Growth

Financial strength

Returns & efficiency

Price & volume

Corporate calendar

Key people

Company facts

Frequently Asked Questions

What is Pfizer share price today?

What is the 52-week high and low of Pfizer shares?

What is the market capitalisation of Pfizer?

What is the P/E ratio of Pfizer?

How has Pfizer stock performed?

What were Pfizer's latest annual results?

Does Pfizer pay a dividend?

What do analysts recommend for Pfizer shares?

What is the shareholding pattern of Pfizer?

Who are Pfizer's competitors?